Suppr超能文献

立体定向放射外科治疗小细胞肺癌伴1-10个脑转移瘤患者:一项多机构、II期前瞻性临床试验。

Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial.

作者信息

Aizer Ayal A, Tanguturi Shyam K, Shi Diana D, Catalano Paul J, Shin Kee-Young, Ricca Ivy, Johnson Marciana, Benham Grant, Kozono David E, Mak Raymond H, Hertan Lauren, Chipidza Fallon, Krishnan Monica, Pashtan Itai, Peng Luke, Qian Jack M, Shiloh Ron Y, Cagney Daniel N, Sands Jacob, Brown Paul D, Wen Patrick Y, Haas-Kogan Daphne A, Rahman Rifaquat

机构信息

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.

出版信息

J Clin Oncol. 2025 Jul 11:JCO2500056. doi: 10.1200/JCO-25-00056.

Abstract

PURPOSE

Stereotactic radiation (SRS/SRT) as opposed to whole-brain radiation (WBRT) represents the standard of care for patients with a limited number of brain metastases given the relatively favorable toxicity profile associated with stereotactic treatment. However, in patients with small cell lung cancer (SCLC), WBRT remains standard because of a lack of prospective data supporting SRS/SRT and concerns related to intracranial progression and neurologic death when WBRT is omitted. We conducted a single-arm, multicenter, phase II trial of SRS/SRT in patients with SCLC and 1-10 brain metastases to assess neurologic death rates relative to historical controls managed with WBRT (ClinicalTrials.gov identifier: NCT03391362).

METHODS

Patients were eligible if they had SCLC or an extrathoracic small cell primary and 1-10 brain metastases. Previous brain-directed radiation including prophylactic cranial irradiation was not permitted. Neurologic death was defined as marked, progressive, radiographic brain progression accompanied by corresponding neurologic symptomatology without systemic disease progression or systemic symptoms of a life-threatening nature. Close imaging-based surveillance of the brain post-SRS/SRT was used.

RESULTS

Between February 2018 and April 2023, 100 patients were enrolled. The median number of brain metastases was 2 (IQR, 1-4; range, 1-10). The median overall survival was 10.2 months; only 22% of patients required salvage WBRT. In total, 20 neurologic deaths were observed, relative to 64 non-neurologic deaths. The neurologic death rate at 1 year was 11.0% (95% CI, 5.8 to 18.1); the historical rate in patients managed with WBRT was 17.5%.

CONCLUSION

Our prospective, multi-institutional study demonstrated low rates of neurologic death when SRS/SRT as opposed to WBRT is used in patients with SCLC and 1-10 brain metastases who are surveilled closely post-treatment, supporting the utility of stereotactic approaches in this population.

摘要

目的

立体定向放射治疗(SRS/SRT)与全脑放射治疗(WBRT)相比,对于脑转移瘤数量有限的患者而言,鉴于立体定向治疗具有相对良好的毒性特征,它代表了治疗的标准。然而,对于小细胞肺癌(SCLC)患者,WBRT仍然是标准治疗方法,因为缺乏支持SRS/SRT的前瞻性数据,且担心省略WBRT时会出现颅内进展和神经源性死亡。我们开展了一项针对SCLC且有1至10个脑转移瘤患者的SRS/SRT单臂、多中心II期试验,以评估相对于接受WBRT治疗的历史对照患者的神经源性死亡率(ClinicalTrials.gov标识符:NCT03391362)。

方法

患者若患有SCLC或胸外小细胞原发肿瘤且有1至10个脑转移瘤,则符合入选条件。不允许既往进行过包括预防性颅脑照射在内的脑定向放射治疗。神经源性死亡定义为显著的、进行性的影像学脑进展,并伴有相应的神经症状,且无全身疾病进展或危及生命的全身症状。采用基于影像学的密切监测方法对SRS/SRT后的脑部进行监测。

结果

在2018年2月至2023年4月期间,共纳入100例患者。脑转移瘤的中位数为2个(四分位间距,1至4个;范围,1至10个)。中位总生存期为10.2个月;仅22%的患者需要挽救性WBRT。总共观察到20例神经源性死亡,非神经源性死亡64例。1年时的神经源性死亡率为11.0%(95%置信区间,5.8%至18.1%);接受WBRT治疗患者的历史死亡率为17.5%。

结论

我们的前瞻性多机构研究表明,对于SCLC且有1至10个脑转移瘤的患者,与WBRT相比,使用SRS/SRT并在治疗后进行密切监测时,神经源性死亡率较低,这支持了立体定向治疗方法在该人群中的实用性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验